Craig DJ, Crawford EL, Chen H, Grogan EL, Deppen SA, Morrison T, Antic SL, Massion PP, Willey JC. TP53 mutation prevalence in normal airway epithelium as a biomarker for lung cancer risk. BMC cancer. 2023 Aug 23;23(23). 783 p. PMID: 37612638 [PubMed]
There is a need for biomarkers that improve accuracy compared with current demographic risk indices to detect individuals at the highest lung cancer risk. Improved risk determination will enable more effective lung cancer screening and better stratification of lung nodules into high or low-risk category. We previously reported discovery of a biomarker for lung cancer risk characterized by increased prevalence of TP53 somatic mutations in airway epithelial cells (AEC). Here we present results from a validation study in an independent retrospective case-control cohort.